CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies targeting the tumor microenvironment, today announced the presentation of new preclinical treatments and translational data for SRF388, a first-in-class antibody targeting IL-27, at the 2022 American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans , April 8-13, 2022. Data will be presented in a poster session, “Determination of a Recommended Phase 2 Dose (RP2D) for SRF388, a First-in-Class IL-27–Blocking Antibody, in Patients with Advanced Solid Tumors” (Abstract #1137) from 9:00 a.m. to 12:30 p.m. CT on Monday, April 11, 2022.
“We are very pleased to share the compelling preclinical and translational data that allowed us to select the dose for our Phase 2 trials of SRF388,” said Alison O’Neill, MD, Chief Medical Officer. “These data add to the growing body of evidence supporting our belief that IL-27 is a highly immunosuppressive cytokine that serves as an essential regulator of checkpoint protein expression, and treatment with SRF388 arrests signaling. of IL-27. We look forward to providing a clinical update on the program at a scientific conference later in the first half of 2022.”
Summary of SRF388 key data:
The pharmacokinetics (PK) of the dose-escalation phase of the Phase 1 study of SRF388 were linear, with no dose-limiting toxicity reported. The concentration of SRF388 associated with optimal antitumor activity in a preclinical mouse model has been determined to be approximately 20 times higher than the concentration required for complete inhibition of phosphorylated STAT1 in whole blood; this concentration of SRF388 was reached and exceeded in patients at a dose of 10 mg/kg. the concentration of several serum cytokines and chemokines was observed after SRF388 treatment, including a subset of these biomarkers correlated with clinical response. An increase in serum IL-27 levels has been observed after treatment with SRF388, a phenomenon described for other anti-cytokine antibodies with impaired clearance of the cytokine-antibody complex. Translational data from SRF388 supports recommended Phase 2 monotherapy dose selection of 10 mg/kg given intravenously every four weeks, which is being studied in dedicated expansion cohorts in treatment-refractory clear cell renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) in the ongoing Phase 1 study (NCT04374877). The efficacy of ad IL-27 blockade with SRF388 to atezolizumab/bevacizumab in treatment-naïve HCC is also being investigated in a randomized, placebo-controlled Phase 2 study.
The AACR e-poster website will launch on Friday, April 8, 2022, and posters will remain available to registered attendees until Wednesday, July 13, 2022. Poster SRF388 is also available on the Surface Oncology website.
About Surface Oncology Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two proprietary clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on the selective depletion of regulatory T cells in the tumor microenvironment via the targeting of CCR8 ( SRF114). Additionally, Surface has two partnerships with big pharma: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s new investigational cancer immunotherapies are designed to achieve a clinically significant and sustained anti-tumor response and can be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
About SRF388 SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. Surface oncology has identified particular tumor types, including liver, kidney, and lung cancer, where IL-27 appears to play an important role in the tumor’s immunosuppressive microenvironment and may contribute to drug resistance. treatment with checkpoint inhibitors. SRF388 targets the p28-limiting subunit of IL-27, and preclinical studies have shown that treatment with SRF388 blocks the immunosuppressive biological effects of IL-27, resulting in the activation of immune cells in combination with other cancer therapies, including anti-PD-1 therapy, as well as strong anti-tumor effects as monotherapy. Additionally, Surface Oncology has identified a potential biomarker associated with IL-27 that may be useful in helping to identify patients most likely to respond to SRF388. In November 2020, Surface announced that SRF388 had obtained Orphan Drug Designation and Fast Track Designation for the treatment of hepatocellular carcinoma from the FDA.
Caution Regarding Forward-Looking Statements Certain statements contained in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by words such as “believes”, “expects”, “plans”, “potential”, “would” or similar expressions, and the negative form of these terms. These forward-looking statements are based on Surface Oncology’s management’s current beliefs and assumptions regarding future events and information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Surface Oncology’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to Surface Oncology’s ability to successfully develop SRF388, SRF617, SRF114 and its other product candidates through current and future regulatory milestones or filings. timely, if any, potential treatment of Surface Oncology’s product candidates, the risk resulting from preclinical studies or early clinical trials may not be representative of larger clinical trials, the risk that the product candidates of Surface Oncology, including SRF388, SRF617 and SRF114, are not successfully developed or commercialized, the risks associated with Surface Oncology’s reliance on third parties in connection with its manufacturing, clinical trials and its preclinical studies, and the potential impact of COVID-19 on the clinical and preclinical development schedules and operating results of Surface Oncology. Additional risks and uncertainties that could affect Surface Oncology’s future results are included in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 available at of the Securities and Exchange Commission at www.sec.gov and the Surface Oncology website at www.surfaceoncology.com. Additional information about potential risks will be made available in other filings from time to time by Surface Oncology with the Securities and Exchange Commission. In addition, all forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes are reasonable as of this date. Except as required by law, Surface Oncology undertakes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.
Contact Scott Young (617) 865-3250 [email protected]
Copyright 2022 GlobeNewswire, Inc.
/cloudfront-us-east-1.images.arcpublishing.com/dmn/MYRW6ZYOOVCQJHKVOSCBMWUG3I.jpg)